|
DE2236930A1
(de)
|
1971-08-03 |
1973-02-15 |
Cameroun Etat |
Verfahren zur herstellung von desmosterol
|
|
GB1447456A
(en)
|
1973-06-20 |
1976-08-25 |
Teijin Ltd |
Process for preparing desmosterols
|
|
JPS54123371A
(en)
|
1978-03-18 |
1979-09-25 |
Yoshio Katsuta |
Mat for electric mosquitoorepellent incense
|
|
GB8607294D0
(en)
|
1985-04-17 |
1986-04-30 |
Ici America Inc |
Heterocyclic amide derivatives
|
|
JPS6250441A
(ja)
|
1986-06-06 |
1987-03-05 |
Mitsubishi Metal Corp |
すぐれた耐摩耗性を有する炭化物分散型鉄基焼結合金
|
|
DE3823318A1
(de)
|
1988-07-09 |
1990-02-22 |
Bayer Ag |
(hetero)aryloxynaphthaline mit ueber schwefel gebundenen substituenten
|
|
US5229115A
(en)
|
1990-07-26 |
1993-07-20 |
Immunex Corporation |
Adoptive immunotherapy with interleukin-7
|
|
EP0567586B1
(en)
|
1991-01-16 |
1995-07-12 |
Schering Corporation |
Use of interleukin-10 in adoptive immunotherapy of cancer
|
|
TW263508B
(OSRAM)
|
1991-02-12 |
1995-11-21 |
Pfizer |
|
|
US5229109A
(en)
|
1992-04-14 |
1993-07-20 |
Board Of Regents, The University Of Texas System |
Low toxicity interleukin-2 analogues for use in immunotherapy
|
|
DE19523446A1
(de)
|
1995-06-28 |
1997-01-02 |
Bayer Ag |
Benzotriazole
|
|
US6037367A
(en)
|
1995-07-14 |
2000-03-14 |
Smithkline Beecham Corporation |
Substituted-pent-4-ynoic acids
|
|
SK15898A3
(en)
|
1995-08-10 |
1998-06-03 |
Bayer Ag |
Halobenzimidazoles and their use as microbicides
|
|
WO1997024334A1
(en)
|
1995-12-28 |
1997-07-10 |
Fujisawa Pharmaceutical Co., Ltd. |
Benzimidazole derivatives
|
|
WO1997048697A1
(en)
|
1996-06-19 |
1997-12-24 |
Rhone-Poulenc Rorer Limited |
Substituted azabicylic compounds and their use as inhibitors of the production of tnf and cyclic amp phosphodiesterase
|
|
JP2000511558A
(ja)
|
1996-06-21 |
2000-09-05 |
アラーガン・セイルズ・インコーポレイテッド |
レチノイドおよび／またはレチノイド拮抗剤様生物学的活性を有する置換テトラヒドロナフタレンおよびジヒドロナフタレン誘導体
|
|
US6180643B1
(en)
|
1996-11-19 |
2001-01-30 |
Amgen Inc. |
Aryl and heteroaryl substituted fused pyrrole antiinflammatory agents
|
|
US6392010B1
(en)
|
1996-12-19 |
2002-05-21 |
Aventis Pharmaceuticals Inc. |
Process for the solid phase synthesis of aldehyde, ketone, oxime, amine, hydroxamic acid and αβ-unsaturated carboxylic acid and aldehyde compounds
|
|
US6828344B1
(en)
|
1998-02-25 |
2004-12-07 |
Genetics Institute, Llc |
Inhibitors of phospholipase enzymes
|
|
JP4327915B2
(ja)
|
1998-03-30 |
2009-09-09 |
株式会社デ・ウエスタン・セラピテクス研究所 |
スルフォンアミド誘導体
|
|
HK1039325B
(en)
|
1998-09-18 |
2006-02-24 |
Abbott Gmbh & Co. Kg |
4-aminopyrrolopyrimidines as kinase inhibitors
|
|
US6348032B1
(en)
|
1998-11-23 |
2002-02-19 |
Cell Pathways, Inc. |
Method of inhibiting neoplastic cells with benzimidazole derivatives
|
|
US6534535B1
(en)
|
1999-08-12 |
2003-03-18 |
Millennium Pharmaceuticals, Inc. |
Inhibitors of factor Xa
|
|
RS50470B
(sr)
|
1999-08-13 |
2010-03-02 |
Biogen Idec Ma Inc. |
Inhibitori ćelijske adhezije
|
|
CA2386474A1
(en)
|
1999-09-20 |
2001-03-29 |
Takeda Chemical Industries, Ltd. |
Melanin concentrating hormone antagonist
|
|
WO2002014361A2
(en)
|
2000-08-17 |
2002-02-21 |
Agensys, Inc. |
NUCLEIC ACIDS AND CORRESPONDING PROTEINS ENTITLED 83P2H3 AND CaTrF2E11 USEFUL IN TREATMENT AND DETECTION OF CANCER
|
|
CZ20031515A3
(cs)
|
2000-11-09 |
2003-09-17 |
Neopharm, Inc. |
Komplexy SN-38 s lipidem a způsob jejich použití
|
|
TWI239942B
(en)
|
2001-06-11 |
2005-09-21 |
Dainippon Pharmaceutical Co |
N-arylphenylacetamide derivative and pharmaceutical composition containing the same
|
|
ATE515495T1
(de)
|
2001-08-03 |
2011-07-15 |
Schering Corp |
Gamma sekretase inhibitoren
|
|
KR100879693B1
(ko)
|
2001-08-17 |
2009-01-21 |
상꾜 아그로 가부시키가이샤 |
2-시클로프로필-6-메틸페놀
|
|
EP2070949B1
(en)
|
2002-06-10 |
2013-01-16 |
Vaccinex, Inc. |
C35 antibodies and their use in the treatment of cancer
|
|
DE10229777A1
(de)
|
2002-07-03 |
2004-01-29 |
Bayer Ag |
Indolin-Phenylsulfonamid-Derivate
|
|
FR2845382A1
(fr)
|
2002-10-02 |
2004-04-09 |
Sanofi Synthelabo |
Derives d'indazolecarboxamides, leur preparation et leur utilisation en therapeutique
|
|
US7138402B2
(en)
|
2003-09-18 |
2006-11-21 |
Conforma Therapeutics Corporation |
Pyrrolopyrimidines and related analogs as HSP90-inhibitors
|
|
US6894061B2
(en)
|
2002-12-04 |
2005-05-17 |
Wyeth |
Substituted dihydrophenanthridinesulfonamides
|
|
UA80171C2
(en)
|
2002-12-19 |
2007-08-27 |
Pfizer Prod Inc |
Pyrrolopyrimidine derivatives
|
|
JP2006512357A
(ja)
|
2002-12-20 |
2006-04-13 |
ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー |
Ｐｉ３ｋの阻害剤としてのベンゾキサジンおよびその誘導体
|
|
JP4601038B2
(ja)
|
2003-03-26 |
2010-12-22 |
第一三共株式会社 |
インドリルマレイミド類
|
|
US20080199486A1
(en)
|
2003-05-12 |
2008-08-21 |
Yair Argon |
Grp94-based compositions and methods of use thereof
|
|
CA2540364A1
(en)
|
2003-09-26 |
2005-04-07 |
Forbes Medi-Tech Inc. |
Method of inhibiting the expression of a multi-drug resistance genes and inhibiting the production of proteins resulting from the expression of such genes thereby enhancing the effectiveness of chemotherapeutic agents to treat cancers
|
|
WO2005033048A2
(en)
|
2003-09-29 |
2005-04-14 |
The Johns Hopkins University |
Wnt pathway antagonists
|
|
WO2005033288A2
(en)
|
2003-09-29 |
2005-04-14 |
The Johns Hopkins University |
Hedgehog pathway antagonists
|
|
SE0302760D0
(sv)
|
2003-10-20 |
2003-10-20 |
Biovitrum Ab |
New compounds
|
|
US7420059B2
(en)
|
2003-11-20 |
2008-09-02 |
Bristol-Myers Squibb Company |
HMG-CoA reductase inhibitors and method
|
|
WO2005058847A1
(en)
*
|
2003-12-09 |
2005-06-30 |
F. Hoffmann-La Roche Ag |
Benzoxazine derivatives and uses thereof
|
|
DE602004025504D1
(de)
|
2003-12-23 |
2010-03-25 |
Novartis Ag |
Bicyclische heterocyclische p-38-kinase-inhibitoren
|
|
WO2005084208A2
(en)
|
2004-02-27 |
2005-09-15 |
New York University |
A novel class of sterol ligands and their uses in regulation of cholesterol and gene expression
|
|
WO2005120558A2
(en)
|
2004-05-25 |
2005-12-22 |
University Of Connecticut Health Center |
Methods for making compositions comprising heat shock proteins or alpha-2-macroglobulin for the treatment of cancer and infectious disease
|
|
CA2571710A1
(en)
|
2004-06-24 |
2006-11-02 |
Nicholas Valiante |
Small molecule immunopotentiators and assays for their detection
|
|
EP1771204A4
(en)
|
2004-07-01 |
2008-08-13 |
Univ New York |
COMPOSITIONS AND METHOD FOR MODULATING ROR-GAMMA-T
|
|
FR2874011B1
(fr)
|
2004-08-03 |
2007-06-15 |
Sanofi Synthelabo |
Derives de sulfonamides, leur preparation et leur application en therapeutique
|
|
US20070010537A1
(en)
|
2004-08-20 |
2007-01-11 |
Kazumasa Hamamura |
Fused pyramidine derivative and use thereof
|
|
US7304073B2
(en)
|
2004-08-20 |
2007-12-04 |
Wyeth |
Method of treating myocardial ischemia-reperfusion injury using NF-kB inhibitors
|
|
US7652043B2
(en)
|
2004-09-29 |
2010-01-26 |
The Johns Hopkins University |
WNT pathway antagonists
|
|
EP1809321B1
(en)
|
2004-10-08 |
2012-03-14 |
Government of the United States of America, Represented by the Secretary, Department of Health and Human Services |
Adoptive immunotherapy with enhanced t lymphocyte survival
|
|
JP2008521406A
(ja)
|
2004-11-24 |
2008-06-26 |
フレッド ハッチンソン キャンサー リサーチ センター |
養子免疫療法のためのｉｌ−２１の使用法および腫瘍抗原の同定法
|
|
AR051780A1
(es)
|
2004-11-29 |
2007-02-07 |
Japan Tobacco Inc |
Compuestos en anillo fusionados que contienen nitrogeno y utilizacion de los mismos
|
|
GB0514911D0
(en)
|
2005-07-20 |
2005-08-24 |
Univ Birmingham |
T cell memory assay
|
|
US8003624B2
(en)
|
2005-08-25 |
2011-08-23 |
Schering Corporation |
Functionally selective ALPHA2C adrenoreceptor agonists
|
|
WO2007024944A1
(en)
|
2005-08-25 |
2007-03-01 |
Schering Corporation |
Imidazole derivatives as functionally selective alpha2c adrenoreceptor agonists
|
|
EP1937669B9
(en)
|
2005-09-01 |
2012-07-18 |
Janssen Pharmaceutica NV |
Novel benzopyran derivatives as potassium channel openers
|
|
JP4843040B2
(ja)
|
2005-09-15 |
2011-12-21 |
エフ．ホフマン−ラ ロシュ アーゲー |
肝カルニチンパルミトイルトランスフェラーゼのインヒビターとして有用な新規ヘテロ二環式誘導体
|
|
FR2896798A1
(fr)
|
2006-01-27 |
2007-08-03 |
Sanofi Aventis Sa |
Derives de sulfonamides, leur preparation et leur application en therapeutique
|
|
ATE550329T1
(de)
|
2006-02-13 |
2012-04-15 |
Hoffmann La Roche |
Heterobicyclische sulfonamidderivate zur behandlung von diabetes
|
|
US7659280B2
(en)
|
2006-02-17 |
2010-02-09 |
Rigel Pharmaceuticals, Inc. |
2,4-pyrimidinediamine compounds for treating or preventing autoimmune diseases
|
|
WO2007103009A2
(en)
|
2006-03-01 |
2007-09-13 |
Janssen Pharmaceutica N.V. |
CANCER TREATMENT COMBINING LYMPHODEPLETING AGENT WITH CTLs AND CYTOKINES
|
|
CA2646093A1
(en)
|
2006-04-06 |
2007-10-11 |
Tibotec Pharmaceuticals Ltd. |
A homogeneous time resolved fluorescence based test system
|
|
US7998978B2
(en)
|
2006-05-01 |
2011-08-16 |
Pfizer Inc. |
Substituted 2-amino-fused heterocyclic compounds
|
|
US20080305169A1
(en)
|
2006-05-26 |
2008-12-11 |
Japan Tobacco Inc. |
Pharmaceutical Compositions Comprising Nitrogen-Containing Fused Ring Coumpounds
|
|
MX2008015329A
(es)
|
2006-06-01 |
2008-12-12 |
Wyeth Corp |
Derivados 1-sulfonilindazolilamina y -amida como ligandos de 5-hidroxitriptamina-6.
|
|
ES2398299T3
(es)
|
2006-07-03 |
2013-03-15 |
Proximagen Ltd. |
Indoles como moduladores de 5-HT6
|
|
US7973135B2
(en)
|
2006-07-12 |
2011-07-05 |
Oncotx, Inc. |
Compositions and methods for targeting cancer-specific transcription complexes
|
|
TWI315304B
(en)
|
2006-08-31 |
2009-10-01 |
Univ Taipei Medical |
Indoline-sulfonamides compounds
|
|
US8389739B1
(en)
|
2006-10-05 |
2013-03-05 |
Orphagen Pharmaceuticals |
Modulators of retinoid-related orphan receptor gamma
|
|
WO2008045664A2
(en)
|
2006-10-06 |
2008-04-17 |
Kalypsys, Inc. |
Heterocyclic pde4 inhibitors as antiinflammatory agents
|
|
WO2008062740A1
(fr)
|
2006-11-20 |
2008-05-29 |
Japan Tobacco Inc. |
Composé azoté à anneaux fusionnés et son utilisation
|
|
US7799933B2
(en)
|
2006-12-21 |
2010-09-21 |
Hoffman-La Roche Inc. |
Sulfonamide derivatives
|
|
US20080186971A1
(en)
|
2007-02-02 |
2008-08-07 |
Tarari, Inc. |
Systems and methods for processing access control lists (acls) in network switches using regular expression matching logic
|
|
WO2008150827A1
(en)
|
2007-05-29 |
2008-12-11 |
Smithkline Beecham Corporation |
Naphthyridine, derivatives as p13 kinase inhibitors
|
|
JP2010529843A
(ja)
|
2007-06-03 |
2010-09-02 |
オンコティーエックス インコーポレイテッド |
バイオマーカーおよび薬物標的としての、転写因子複合体の構成要素のがん関連アイソフォーム
|
|
US7776877B2
(en)
|
2007-06-22 |
2010-08-17 |
Chemocentryx, Inc. |
N-(2-(hetaryl)aryl) arylsulfonamides and N-(2-(hetaryl) hetaryl arylsulfonamides
|
|
JP2010538003A
(ja)
|
2007-08-29 |
2010-12-09 |
グラクソスミスクライン エルエルシー |
チアゾールおよびオキサゾールキナーゼ阻害薬
|
|
US7960376B2
(en)
|
2007-09-14 |
2011-06-14 |
Cara Therapeutics, Inc. |
Benzo-fused heterocycles
|
|
WO2009040789A2
(en)
|
2007-09-24 |
2009-04-02 |
Technion Research & Development Foundation Ltd. |
T cell subpopulations capable of treating cancer
|
|
US20090131523A1
(en)
|
2007-10-15 |
2009-05-21 |
Enzymotec Ltd. |
Lipid compositions for the treatment and prevention of proliferative diseases and for the reduction of incidences of mutagenesis and carinogenesis
|
|
RU2364597C1
(ru)
|
2007-12-14 |
2009-08-20 |
Андрей Александрович Иващенко |
ГЕТЕРОЦИКЛИЧЕСКИЕ ИНГИБИТОРЫ Hh-СИГНАЛЬНОГО КАСКАДА, ЛЕКАРСТВЕННЫЕ КОМПОЗИЦИИ НА ИХ ОСНОВЕ И СПОСОБ ЛЕЧЕНИЯ ЗАБОЛЕВАНИЙ, СВЯЗАННЫХ С АББЕРАНТНОЙ АКТИВНОСТЬЮ Hh СИГНАЛЬНОЙ СИСТЕМЫ
|
|
US7960377B2
(en)
|
2008-03-28 |
2011-06-14 |
Cara Therapeutics, Inc. |
Substituted pyridoxazines
|
|
ES2566339T3
(es)
|
2008-06-05 |
2016-04-12 |
Glaxo Group Limited |
Derivados de 4-carboxamida indazol útiles como inhibidores de PI3-quinasas
|
|
JP5502077B2
(ja)
|
2008-06-05 |
2014-05-28 |
グラクソ グループ リミテッド |
新規な化合物
|
|
ES2445199T3
(es)
|
2008-06-05 |
2014-02-28 |
Glaxo Group Limited |
Derivados de benzpirazol como inhibidores de PI3-quinasas
|
|
WO2009149819A1
(en)
|
2008-06-09 |
2009-12-17 |
Sanofi-Aventis |
Annelated pyrrolidin sulfonamides with oxadiazolone headgroup, processes for their preparation and their use as pharmaceuticals
|
|
RU2010154279A
(ru)
|
2008-06-09 |
2012-07-20 |
Санофи-Авентис (Fr) |
Аннелированные n-гетероциклические сульфонамиды с оксадиазолоновой концевой группой, способы их получения и их применение в качестве фармацевтических препаратов
|
|
US9334242B2
(en)
|
2008-06-16 |
2016-05-10 |
Gtx, Inc. |
Compounds for treatment of cancer
|
|
EP2298731A4
(en)
|
2008-06-25 |
2011-09-21 |
Takeda Pharmaceutical |
AMIDE COMPOUND
|
|
KR101608456B1
(ko)
|
2008-07-09 |
2016-04-01 |
닛산 가가쿠 고교 가부시키 가이샤 |
이속사졸린 치환 안식향산 아미드 화합물의 제조 방법
|
|
WO2010017827A1
(en)
|
2008-08-14 |
2010-02-18 |
European Molecular Biology Laboratory |
6-substituted 1-sulfonyl-2, 3-dihydro-indole derivatives for the treatment of proliferative diseases
|
|
JP2012508561A
(ja)
|
2008-09-11 |
2012-04-12 |
ユニバーシティ オブ フロリダ リサーチファウンデーション インコーポレイティッド |
Ｔ細胞を産生するためのシステム及び方法
|
|
RU2498981C2
(ru)
|
2008-10-02 |
2013-11-20 |
Тайсо Фармасьютикал Ко., Лтд. |
7-пиперидиноалкил-3,4-дигидрохинолоновые производные, обладающие антагонистическим действием на рецептор мсн (меланин-концентрирующего гормона)
|
|
EP2181710A1
(en)
|
2008-10-28 |
2010-05-05 |
Phenex Pharmaceuticals AG |
Ligands for modulation of orphan receptor-gamma (NR1F3) activity
|
|
WO2010057101A2
(en)
|
2008-11-17 |
2010-05-20 |
Schering Corporation |
Compounds useful as hiv blockers
|
|
EP2367598B1
(en)
|
2008-11-19 |
2014-04-09 |
Merck Sharp & Dohme Corp. |
Inhibitors of diacylglycerol acyltransferase
|
|
EP2352756B1
(en)
|
2008-11-24 |
2012-09-19 |
Helmholtz Zentrum München Deutsches Forschungszentrum für Gesundheit und Umwelt GmbH |
High affinity t cell receptor and use thereof
|
|
BRPI0922435A2
(pt)
|
2008-12-19 |
2018-09-11 |
Sirtris Pharmaceuticals Inc |
"composto de tiazolopiridina moduladores de sirtuina, composição farmacêutica compreendendo o mesmo e seu uso."
|
|
TW201030007A
(en)
|
2009-02-06 |
2010-08-16 |
Gruenenthal Gmbh |
Substituted spiro-amides as b1r modulators
|
|
US8524751B2
(en)
|
2009-03-09 |
2013-09-03 |
GlaxoSmithKline Intellecutual Property Development |
4-oxadiazol-2-YL-indazoles as inhibitors of P13 kinases
|
|
TW201102391A
(en)
|
2009-03-31 |
2011-01-16 |
Biogen Idec Inc |
Certain substituted pyrimidines, pharmaceutical compositions thereof, and methods for their use
|
|
WO2010123139A1
(ja)
|
2009-04-24 |
2010-10-28 |
持田製薬株式会社 |
スルファモイル基を有するアリールカルボキサミド誘導体
|
|
ES2644724T3
(es)
|
2009-04-30 |
2017-11-30 |
Glaxo Group Limited |
Indazoles sustituidos con oxazol como inhibidores de PI3-cinasas
|
|
SG178125A1
(en)
|
2009-08-03 |
2012-03-29 |
Univ Miami |
Method for in vivo expansion of t regulatory cells
|
|
US8119683B2
(en)
|
2009-08-10 |
2012-02-21 |
Taipei Medical University |
Aryl substituted sulfonamide compounds and their use as anticancer agents
|
|
US8383099B2
(en)
|
2009-08-28 |
2013-02-26 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Adoptive cell therapy with young T cells
|
|
AR078770A1
(es)
|
2009-10-27 |
2011-11-30 |
Elara Pharmaceuticals Gmbh |
Derivados de dihidrobenzo oxacinas y tiazinas, composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento de enfermedades inflamatorias e hiperproliferativas.
|
|
WO2011059839A1
(en)
|
2009-10-29 |
2011-05-19 |
Sirtris Pharmaceuticals, Inc. |
Bicyclic pyridines and analogs as sirtuin modulators
|
|
EP2507226A1
(en)
|
2009-12-03 |
2012-10-10 |
Glaxo Group Limited |
Novel compounds
|
|
US20120238571A1
(en)
|
2009-12-03 |
2012-09-20 |
Glaxo Group Limited |
Indazole derivatives as pi 3-kinase
|
|
JP2013512879A
(ja)
|
2009-12-03 |
2013-04-18 |
グラクソ グループ リミテッド |
Ｐｉ３キナーゼの阻害剤としてのベンズピラゾール誘導体
|
|
US8956860B2
(en)
|
2009-12-08 |
2015-02-17 |
Juan F. Vera |
Methods of cell culture for adoptive cell therapy
|
|
US20110142814A1
(en)
|
2009-12-16 |
2011-06-16 |
New York University |
Methods for Using Protein Kinase C-Theta Inhibitors in Adoptive Immunotherapy
|
|
JP6066732B2
(ja)
|
2010-03-05 |
2017-01-25 |
ザ・ジョンズ・ホプキンス・ユニバーシティー |
標的免疫調節抗体および融合タンパク質に基づく組成物および方法
|
|
WO2011115892A1
(en)
|
2010-03-15 |
2011-09-22 |
Griffin Patrick R |
Modulators of the retinoic acid receptor-related orphan receptors
|
|
GB201004551D0
(en)
|
2010-03-19 |
2010-05-05 |
Immatics Biotechnologies Gmbh |
NOvel immunotherapy against several tumors including gastrointestinal and gastric cancer
|
|
GB201013443D0
(en)
|
2010-08-11 |
2010-09-22 |
Cytovac As |
Compositions and methods for producing dendritic cells
|
|
HUE026059T2
(en)
|
2010-09-08 |
2016-05-30 |
Glaxosmithkline Ip Dev Ltd |
N- [5- [4- (5 - {[(2R, 6S) -2,6-dimethyl-4-morpholinyl] methyl} -1,3-oxazol-2-yl) -1H-indazol-6-yl ] Polymorphs and salts of 2 - (methyloxy) -3-pyridinyl] methanesulfonamide
|
|
JP5876051B2
(ja)
|
2010-09-08 |
2016-03-02 |
グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ |
インフルエンザウィルス感染の治療に使用するためのインダゾール誘導体
|
|
US9212134B2
(en)
|
2010-09-13 |
2015-12-15 |
Microbiotix, Inc. |
Inhibitors of viral entry into mammalian cells
|
|
WO2012037108A1
(en)
|
2010-09-13 |
2012-03-22 |
Glaxosmithkline Llc |
Aminoquinoline derivatives as antiviral agents
|
|
AU2011326071A1
(en)
*
|
2010-11-08 |
2013-05-23 |
Lycera Corporation |
N- sulfonylated tetrahydroquinolines and related bicyclic compounds inhibition of RORy activity and the treatment of diseases
|
|
PH12013501201A1
(en)
|
2010-12-09 |
2013-07-29 |
Univ Pennsylvania |
Use of chimeric antigen receptor-modified t cells to treat cancer
|
|
EP2487159A1
(en)
|
2011-02-11 |
2012-08-15 |
MSD Oss B.V. |
RorgammaT inhibitors
|
|
EP3184117B1
(en)
|
2011-03-22 |
2020-01-08 |
The Brigham And Women's Hospital, Inc. |
Compositions and their use in the treatment of cancer
|
|
CN110200997A
(zh)
|
2011-03-23 |
2019-09-06 |
弗雷德哈钦森癌症研究中心 |
用于细胞免疫治疗的方法和组合物
|
|
WO2012127464A2
(en)
|
2011-03-23 |
2012-09-27 |
Gavish-Galilee Bio Applications Ltd |
Constitutively activated t cells for use in adoptive cell therapy
|
|
WO2012130306A1
(en)
|
2011-03-30 |
2012-10-04 |
Elara Pharmaceuticals Gmbh |
Bicyclic 2,3-dihyrdobenzazine compounds for use in therapy
|
|
EP2511263A1
(en)
|
2011-04-14 |
2012-10-17 |
Phenex Pharmaceuticals AG |
Pyrrolo sulfonamide compounds for modulation of orphan nuclear receptor RAR-related orphan receptor-gamma (RORgamma, NR1F3) activity and for the treatment of chronic inflammatory and autoimmune diseases
|
|
WO2012158784A2
(en)
|
2011-05-16 |
2012-11-22 |
Theodore Mark Kamenecka |
Modulators of the nuclear hormone receptor ror
|
|
EP3616701A1
(en)
|
2011-06-24 |
2020-03-04 |
GRI Bio, Inc. |
Prevention and treatment of inflammatory conditions
|
|
PL2758060T3
(pl)
|
2011-09-19 |
2018-04-30 |
ETH Zürich |
Modulatory ROR-gamma do leczenia powikłań cukrzycy typu II
|
|
GB201116641D0
(en)
|
2011-09-27 |
2011-11-09 |
Glaxo Group Ltd |
Novel compounds
|
|
US10391126B2
(en)
|
2011-11-18 |
2019-08-27 |
Board Of Regents, The University Of Texas System |
CAR+ T cells genetically modified to eliminate expression of T-cell receptor and/or HLA
|
|
RU2627185C1
(ru)
|
2012-03-16 |
2017-08-03 |
Коваген Аг |
Новые связывающие молекулы с противоопухолевой активностью
|
|
US9266827B2
(en)
|
2012-05-08 |
2016-02-23 |
Merck Sharp & Dohme Corp. |
Bicyclic sulfone compounds for inhibition of RORgamma activity and the treatment of disease
|
|
MX367341B
(es)
|
2012-05-08 |
2019-08-14 |
Merck Sharp & Dohme |
Tetrahidronaftiridina y compuestos biciclicos relacionados para la inhibicion de la actividad de rorgamma y el tratamiento de enfermedades.
|
|
US9394315B2
(en)
|
2012-05-08 |
2016-07-19 |
Lycera Corporation |
Tetrahydro[1,8]naphthyridine sulfonamide and related compounds for use as agonists of RORγ and the treatment of disease
|
|
WO2013167136A1
(en)
|
2012-05-08 |
2013-11-14 |
Herlev Hospital |
Improving adoptive cell therapy with interferon gamma
|
|
JP6220388B2
(ja)
|
2012-05-25 |
2017-10-25 |
ヘルス・ダイアグノスティック・ラボラトリー，インコーポレーテッド |
ステロール／スタノール又はそれらの誘導体の迅速でハイスループットの分析
|
|
WO2014028669A1
(en)
|
2012-08-15 |
2014-02-20 |
Biogen Idec Ma Inc. |
Novel compounds for modulation of ror-gamma activity
|
|
WO2014026329A1
(en)
|
2012-08-15 |
2014-02-20 |
Merck Sharp & Dohme Corp. |
N-alkylated indole and indazole compounds as rorgammat inhibitors and uses thereof
|
|
WO2014026330A1
(en)
|
2012-08-15 |
2014-02-20 |
Merck Sharp & Dohme Corp. |
3-AMINOCYCLOALKYL COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF
|
|
WO2014026327A1
(en)
|
2012-08-15 |
2014-02-20 |
Merck Sharp & Dohme Corp. |
4-heteroaryl substituted benzoic acid compounds as rorgammat inhibitors and uses thereof
|
|
WO2014026328A1
(en)
|
2012-08-15 |
2014-02-20 |
Merck Sharp & Dohme Corp. |
3-cyclohexenyl substituted indole and indazole compounds as rorgammat inhibitors and uses thereof
|
|
ES2702315T3
(es)
|
2012-08-24 |
2019-02-28 |
Univ California |
Anticuerpos y vacunas para su uso en tratar cánceres ROR1 e inhibir metástasis
|
|
EP2931267A1
(en)
|
2012-12-17 |
2015-10-21 |
INSERM - Institut National de la Santé et de la Recherche Médicale |
Methods and pharmaceutical compositions for the treatment of x-linked charcot-marie-tooth
|
|
US20150017120A1
(en)
|
2013-06-13 |
2015-01-15 |
Massachusetts Institute Of Technology |
Synergistic tumor treatment with extended-pk il-2 and adoptive cell therapy
|
|
CN105705501B
(zh)
*
|
2013-09-09 |
2019-04-19 |
百时美施贵宝公司 |
RORγ调节剂
|
|
WO2015095795A1
(en)
|
2013-12-20 |
2015-06-25 |
Merck Sharp & Dohme Corp. |
TETRAHYDRONAPHTHYRIDINE, BENZOXAZINE, AZA-BENZOXAZINE, AND RELATED BICYCLIC COMPOUNDS FOR INHIBITION OF RORgamma ACTIVITY AND THE TREATMENT OF DISEASE
|
|
WO2015095792A1
(en)
|
2013-12-20 |
2015-06-25 |
Merck Sharp & Dohme Corp. |
Carbamate benzoxaxine propionic acids and acid derivatives for modulation of rorgamma activity and the treatment of disease
|
|
WO2015095788A1
(en)
|
2013-12-20 |
2015-06-25 |
Merck Sharp & Dohme Corp. |
2-ACYLAMIDOMETHYL AND SULFONYLAMIDOMETHYL BENZOXAZINE CARBAMATES FOR INHIBITION OF RORgamma ACTIVITY AND THE TREATMENT OF DISEASE
|
|
CA2939305A1
(en)
|
2014-02-27 |
2015-09-03 |
Lycera Corporation |
Adoptive cellular therapy using an agonist of retinoic acid receptor-related orphan receptor gamma & related therapeutic methods
|
|
CA2947290A1
(en)
|
2014-05-05 |
2015-11-12 |
Lycera Corporation |
Tetrahydroquinoline sulfonamide and related compounds for use as agonists of rory and the treatment of disease
|
|
WO2015171558A2
(en)
|
2014-05-05 |
2015-11-12 |
Lycera Corporation |
BENZENESULFONAMIDO AND RELATED COMPOUNDS FOR USE AS AGONISTS OF RORγ AND THE TREATEMENT OF DISEASE
|
|
JP2018515491A
(ja)
|
2015-05-05 |
2018-06-14 |
リセラ・コーポレイションＬｙｃｅｒａ Ｃｏｒｐｏｒａｔｉｏｎ |
ＲＯＲγの作動薬及び疾患の療法として使用するジヒドロ−２Ｈ−ベンゾ［ｂ］［１，４］オキサジンスルホンアミド及び関連化合物
|
|
EP3307738B1
(en)
|
2015-06-11 |
2022-04-20 |
The Regents of the University of Michigan |
Aryl dihydro-2h-benzo[b][1,4]oxazine sulfonamide and related compounds for use as agonists of rory and the treatment of disease
|
|
WO2018165501A1
(en)
|
2017-03-10 |
2018-09-13 |
Lycera Corporation |
INDOLINYL SULFONAMIDE AND RELATED COMPOUNDS FOR USE AS AGONISTS OF RORγ AND THE TREATMENT OF DISEASE
|